Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

Eric J. Jaehnig(Baylor College of Medicine), Meenakshi Anurag(Baylor College of Medicine), Shankha Satpathy(Broad Institute), Matthew V. Holt(Baylor College of Medicine), Shyam M. Kavuri(Baylor College of Medicine), Viktoriya Korchina(Baylor College of Medicine), Steven A. Carr(Broad Institute), George Miles(Baylor College of Medicine), Donna M. Muzny(Baylor College of Medicine), D.R. Mani(Broad Institute), Azra Krek(Icahn School of Medicine at Mount Sinai), HarshaVardhan Doddapaneni(Baylor College of Medicine), Lisa A. Carey(UNC Lineberger Comprehensive Cancer Center), Jonathan T. Lei(Baylor College of Medicine), Richard A. Gibbs(Baylor College of Medicine), Yujia Wen(National Cancer Institute), Beom-Jun Kim(Baylor College of Medicine), LaTerrica Williams(Baylor College of Medicine), Terry Hyslop(Duke Cancer Institute), Charles M. Perou(Segeberger Kliniken), Linda McCart(Alliance for Clinical Trials in Oncology), Yongchao Dou(Baylor College of Medicine), Michael A. Gillette(Broad Institute), Aranzazu Fernandez-Martinez(University of North Carolina at Chapel Hill), Ana I. Robles(National Cancer Institute), Chang In Moon(Baylor College of Medicine), Matthew J. Ellis(Children's Cancer Center), Francesca Petralia(Icahn School of Medicine at Mount Sinai), Tanmayi D. Vashist(Broad Institute), Bing Zhang(Baylor College of Medicine), Haoquan Zhao(Baylor College of Medicine)
Cell Reports Medicine
June 1, 2025
Cited by 3


Related Papers